BioSpace News Archive

Oxford BioDynamics, Plc. announced validation of its EpiSwitch Prostate Screening blood test in its US clinical laboratory, resulting in the immediate access to its highly accurate PSE test to men with prostate cancer risk.

Recently has unveiled a remarkable announcement: the inauguration of the Huahai Institute of Vitiligo Research in Shanghai.

Moon Surgical, a French-American pioneer in collaborative robotics, announced that Baptist Health performed the first clinical procedures in the United States using the Maestro System.

In a major achievement, Avalo Therapeutics proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab in patients with prurigo nodularis (PN) has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on Nov 5-7, 2023.

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”) today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients.

In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award.

AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria.

With a more connected and efficient digital lab process, Health Gorilla and Amwell reinforce their commitment to accessible hybrid care.

Anthos Therapeutics, Inc. announced that primary data from the AZALEA-TIMI 71 study of patients with atrial fibrillation at moderate-to-high risk of stroke has been selected for a Late Breaking session at the American Heart Association Scientific Sessions 2023, being held November 11-13 in Philadelphia.